Instrument NameAbbvie IncInstrument Symbol(ABBV-N)

Instrument ExchangeNYSE

Most pharmaceutical businesses are slow-moving by nature due to the lengthy amount of time it takes to develop a new medicine, and AbbVie (NYSE: ABBV) is no exception. Nonetheless, the next five years will likely see it growing faster than the...

Last year, pharmaceutical giant AbbVie (NYSE: ABBV) lost patent exclusivity for its biggest cash cow, immunology medicine Humira. The drugmaker has rebounded quite nicely since. AbbVie returned to top-line growth in the second quarter, much...

These three companies all have one thing in common: they are all on sale.

The drugmaker has convincingly laid to rest the biggest threat to its top line.

These companies have solid businesses and excellent dividend growth track records.

As the biopharma industry booms with breakthrough treatments and growing demand, this high-yield healthcare stock just received a strong vote of confidence from insider buying.

Most U.S. stocks rose on Wall Street, but drops for Nvidia and some other heavyweight Big Tech companies kept indexes in check

The S&P 500 Index ($SPX ) (SPY ) Monday closed up +0.10%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.69%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.05%. Stocks on Monday settled mixed, with the S&P 500 and the Dow Jones Industrials...

A splashy recent acquisition by the company might not be panning out.

This might be the perfect opportunity to buy this growth and income stock at a discount.

The S&P 500 Index ($SPX ) (SPY ) today is up +0.28%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.94%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.07%. Stocks today are moderately higher, with the S&P 500 and the Dow Jones Industrials...

The S&P 500 Index ($SPX ) (SPY ) today is up +0.21%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +1.02%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.19%. Stocks today are moderately higher, with the S&P 500 and the Dow Jones Industrials...

High yields aren't a warning indicator with these three stocks.

This Dividend King truly wears the crown.

You can be a little greedy sometimes and find great stocks that possess solid growth prospects and also pay dividends.

Eli Lilly's price pullback is an opportunity worth 25%, with analysts' sentiment firming around the $1000 level. New highs are likely by early 2025.

After strong earnings reports, Merck may be a better choice than Bristol-Meyers in the short term - but both may present a challenge for buy-and-hold investors.

Exchange-traded funds (ETFs) are often associated with a lot of diversification. People often invest ...

High-yielding AbbVie is on track for another 20% gain, which could happen by the end of the year. Analysts are raising their targets, leading to higher prices.

It's hard to beat the power of dividend-paying stocks. They have outperformed non-payers significantly.

ABBV earnings call for the period ending September 30, 2024.

These 3 dividend growth stocks have crushed the market and show no signs of slowing down.

December Nasdaq 100 E-Mini futures (NQZ24) are trending up +0.28% this morning as strong quarterly results from Alphabet boosted sentiment, while investors also awaited a fresh batch of U.S. economic data and earnings reports from “Magnificent Seven” companies Microsoft and Meta.

/CNW/ - AbbVie (NYSE: ABBV) announced today that Ontario has listed VRAYLAR® (cariprazine) on its provincial formulary as a General Benefit. The listing will...

These healthcare stocks have fantastic dividend track records.